Physician profile
James E Lusby
NPI 1003851510
$5,417.13
in general payments reported to CMS, 2019-2025
28 companies · $1,191 in 2025
The $1,191 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $134 · 2021: $515 · 2022: $636 · 2023: $1,283 · 2024: $992 · 2025: $1,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,465.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,999.77 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $781.21 | 2019-2025 | Entyvio |
| Pfizer INC. | $545.73 | 2019-2025 | |
| Janssen Biotech, INC. | $440.37 | 2019-2025 | Stelara, Tremfya, Simponi |
| Genzyme Corporation | $244.89 | 2021-2025 | |
| Gilead Sciences, INC. | $205.90 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $162.00 | 2024-2025 | Voquezna |
| Olympus America INC. | $146.76 | 2019 | |
| Intercept Pharmaceuticals, INC. | $146.58 | 2019-2025 | Ocaliva |
| Qol Medical, LLC | $90.01 | 2024-2025 | Sucraid, Sucraid |
| Celgene Corporation | $83.10 | 2023-2024 | Zeposia |
| Ucb, INC. | $69.13 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.33 | 2023 | Cyltezo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.94 | 2021-2024 | Trulance |
| Ardelyx, INC. | $57.63 | 2023-2025 | Ibsrela |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $45.41 | 2024 | Zeposia |
| Mallinckrodt Hospital Products INC. | $35.19 | 2025 | Terlivaz |
| Madrigal Pharmaceuticals | $26.98 | 2025 | Rezdiffra |
| Lilly USA, LLC | $25.79 | 2025 | Omvoh |
| Amgen INC. | $23.77 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $23.42 | 2025 | Dupixent |
| Mylan Institutional INC. | $21.27 | 2023 | Hulio |
| Daiichi Sankyo INC. | $20.25 | 2024 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $19.71 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $19.56 | 2019 | |
| Novo Nordisk INC | $17.03 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $16.52 | 2023 | |
| Allergan, INC. | $13.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lusby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.